Compare Cytokinetics Inc (CYTK) vs iShares MSCI South Korea ETF (EWY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs iShares MSCI South Korea ETF — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while iShares MSCI South Korea ETF trades at $177.22 (market cap $26.25B). The key difference: iShares MSCI South Korea ETF is far larger — about 3× Cytokinetics Inc's market cap, and iShares MSCI South Korea ETF is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and iShares MSCI South Korea ETF for 47 Days on average.
| CYTK | EWY | |
|---|---|---|
Market Cap | $8.62B | $26.25B |
Volume | 2,594,626 | 19,056,075 |
Sector | Health | Broad Market / Factor |
52-Week High | $87.26 | $219.20 |
52-Week Low | $54.76 | $80.72 |
Typical Hold Time | 19 Days | 47 Days |
Enterprise Value | $8.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $62.01, up 1.46% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported Q2 2026 EPS of -$1.50, beating expectations, but maintains deeply negative profitability with a net income margin of -1,321.12% for 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy studies and presentations at major medical conferences.
Wall Street sentiment is overwhelmingly bullish with a 97.14% buy rating and a $112.60 consensus price target, signaling strong upside potential. However, high cash burn, substantial losses, and significant debt-to-asset ratio of 81.23% present substantial financial risks. Investment appeal hinges on successful commercialization of its pipeline amid intense competition.
EWY is trading at $176.33, down 4.02% amid bearish technical signals, with moving averages indicating selling pressure. The ETF faces headwinds from rising US yields and oil prices impacting South Korean tech stocks, though RSI levels suggest potential oversold conditions. Recent volatility reflects sensitivity to AI sector dynamics and global macroeconomic factors.
Outlook remains cautious due to concentrated exposure to semiconductor giants Samsung and SK Hynix, creating dependency on memory cycle strength. Investment opportunity exists if AI demand sustains earnings growth, but risks include Fed policy impacts and geopolitical tensions. Governance reforms and deleveraging provide fundamental support amid market turbulence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →
